Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for TransThera Sciences (Nanjing)'s Net Margin % or its related term are showing as below:
FRA:J8J's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -76.745 * Ranked among companies with meaningful Net Margin % only.
TransThera Sciences (Nanjing) (FRA:J8J) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
TransThera Sciences (Nanjing) Net Margin % Related Terms
TransThera Sciences (Nanjing) Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) Net Margin % Chart
TransThera Sciences (Nanjing) Annual Data
Trend
Dec23
Dec24
Dec25
Net Margin %
-29,013.82
0.00
0.00
TransThera Sciences (Nanjing) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Net Margin %
0.00
0.00
0.00
0.00
0.00
FRA:J8J vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransThera Sciences (Nanjing) Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s Net Margin % distribution charts can be found below:
* The bar in red indicates where TransThera Sciences (Nanjing)'s Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) (FRA:J8J) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on TransThera Sciences (Nanjing) and its competitors. According to the industry distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 944 companies in the Biotechnology industry.
Is TransThera Sciences (Nanjing)'s Net Margin % too high?
TransThera Sciences (Nanjing)'s current Net Margin % is 0.00%. Based on the distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 944 companies for Net Margin %. This places TransThera Sciences (Nanjing) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score
Get the complete analysis for FRA:J8J
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8J has been successfully added to your 
